Roche's cancer immunotherapy TECENTRIQ (atezolizumab) approved in Switzerland for people with a specific type of metastatic lung cancer Montag, 12. Juni 2017 - 07:00
Roche's cancer immunotherapy TECENTRIQ (atezolizumab) approved in Switzerland for people with a specific type of metastatic lung cancer | |
|---|
|
|---|
| First and only anti-PD-L1 cancer immunotherapy approved by Swissmedic for metastatic non small cell lung cancer (NSCLC) |
|---|
|
|---|
| Significant survival benefit of TECENTRIQ compared with docetaxel chemotherapy, regardless of PD-L1 status |
|---|
|
|---|
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval to the cancer immunotherapy TECENTRIQ® (atezolizumab). TECENTRIQ is used to treat people with locally advanced or metastatic non-small cell lung cancer (NSCLC) following previous treatment with chemotherapy.
The approval is based on results from the randomised Phase III OAK and Phase II POPLAR studies. The OAK study showed that TECENTRIQ helped people live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy (median overall survival [OS]: 13.8 vs 9.6 months; HR = 0.73, 95% CI: 0.62–0.87), regardless of their levels of programmed death-ligand 1 (PD-L1) expression.
 More |
|---|
|
|---|
 170612 TECENTRIQ Switzerland_en.pdf |
|---|
|
|---|
|
|---|
|
|---|
